慢性閉塞性肺疾患（COPD）治療市場：薬剤クラス別、投与経路別、流通チャネル別、地域別

慢性閉塞性肺疾患（COPD）治療の世界市場は、2025年には203億5,000万米ドルと推定され、2032年には304億1,000万米ドルに達すると予測され、2025年から2032年までの年間平均成長率（CAGR）は5.9%で成長する見込みです。

図.慢性閉塞性肺疾患（COPD）治療市場シェア（%）、2025年地域別

慢性閉塞性肺疾患（COPD）は、気流の閉塞や呼吸関連の問題を引き起こす肺疾患群を指します。肺気腫と慢性気管支炎が含まれます。COPDの主な原因としては、タバコの喫煙、粉塵や煙などの職場での肺刺激物質への暴露、大気汚染などが挙げられます。COPDの主な症状には、息切れ、咳、粘液（痰）の分泌、喘鳴などがあります。COPDが進行すると、時間とともに肺機能が低下し、息苦しさが生じる。

市場力学：

世界の慢性閉塞性肺疾患（COPD）治療市場の成長は、タバコの喫煙率の高さ、世界の大気汚染レベルの上昇、高齢者人口の増加、疾患と利用可能な治療オプションに対する意識の高まりなどの要因によってもたらされます。しかし、COPDや肺がんのような関連合併症の完全な治療法がないことが市場成長の妨げになる可能性があります。製薬会社はCOPDの新規生物学的製剤の研究開発に投資しており、市場成長に有利な機会を提供できます。企業はCOPDの症状や増悪を効果的に治療するため、エピネフリン自動注射器、気管支拡張薬、吸入コルチコステロイド、併用療法を開発しています。

本調査の主な特徴

• 本レポートでは、世界の慢性閉塞性肺疾患（COPD）治療市場を詳細に分析し、2024年を基準年とした予測期間（2025年～2032年）の市場規模（億米ドル）および複合年間成長率（CAGR%）を掲載しています。
• また、さまざまなセグメントにわたる潜在的な収益成長機会を明らかにし、この市場の魅力的な投資提案マトリックスについて解説しています。
• また、市場促進要因、抑制要因、機会、新製品の上市や承認、市場動向、地域別の展望、主要企業が採用する競合戦略などに関する重要な考察も提供しています。
• 世界の慢性閉塞性肺疾患（COPD）治療市場における主要企業プロファイルを、企業ハイライト、製品ポートフォリオ、主要ハイライト、業績、戦略などのパラメータに基づいて掲載しています。
• 主要企業には、AstraZeneca、Orion Corporation、Mylan N.V.、Teva Pharmaceutical Industries Ltd.、GSK plc、Novartis AG、Sunovion Pharmaceuticals, Inc、CHIESI Farmaceutici SpA, Alembic Pharmaceuticals Ltd, Verona Pharmaceuticals, Theravance Biopharma, F. Hoffmann-La Roche Ltd, Sanofi, Boehringer Ingelheim International GmbH, Merck &Co., Inc, Grifols, S.A., Almirall, S.A., Genentech, Inc.
• 本レポートからの洞察により、マーケティング担当者や企業の経営陣は、将来の製品発売、タイプアップ、市場拡大、マーケティング戦術に関する情報に基づいた意思決定を行うことができます。
• 世界の慢性閉塞性肺疾患（COPD）治療市場は、投資家、サプライヤー、製品メーカー、流通業者、新規参入者、財務アナリストなど、この業界の様々な利害関係者に対応しています。
• 利害関係者は、世界の慢性閉塞性肺疾患（COPD）治療市場の分析に使用される様々な戦略マトリックスを通じて意思決定を容易にすることができます。

第1章 調査の目的と前提条件

• 調査目的
• 前提条件
• 略語

第2章 市場の展望

• レポートの説明
  • 市場の定義と範囲
• エグゼクティブサマリー
• Coherent Opportunity Map（COM）

第3章 市場力学、規制、動向分析

• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• 影響分析
• 疫学
• 市場動向
• 主な発展
• 規制シナリオ
• メーカー収益
• 買収と提携のシナリオ
• 製品の発売/承認
• 資金調達と投資
• PEST分析
• ポーターの分析

第4章 世界の慢性閉塞性肺疾患（COPD）治療市場- コロナウイルス（COVID-19）パンデミックの影響

• 全体的な影響
• 政府の取り組み
• COVID-19による市場への影響

第5章 慢性閉塞性肺疾患（COPD）治療の世界市場、薬剤クラス別、2020年-2032年（10億米ドル）

• 気管支拡張薬
• ホスホジエステラーゼ4阻害剤
• コルチコステロイド
• その他

第6章 慢性閉塞性肺疾患（COPD）治療の世界市場、投与経路別、2020年-2032年、（10億米ドル）

• 経口
• 吸入

第7章 慢性閉塞性肺疾患（COPD）治療の世界市場、流通チャネル別、2020年-2032年、（10億米ドル）

• 病院薬局
• 小売薬局
• オンライン薬局

第8章 慢性閉塞性肺疾患（COPD）治療の世界市場、地域別、2020年-2032年、（10億米ドル）

• 北米
• ラテンアメリカ
• 欧州
• アジア太平洋
• 中東
• アフリカ

第9章 競合情勢

• 企業プロファイル
  • AstraZeneca
  • Orion Corporation
  • Mylan NV
  • Teva Pharmaceutical Industries Ltd.
  • GSK plc
  • Novartis AG
  • Sunovion Pharmaceuticals, Inc.
  • CHIESI Farmaceutici SpA
  • Alembic Pharmaceuticals Ltd
  • Verona Pharmaceuticals
  • Theravance Biopharma
  • F. Hoffmann-La Roche Ltd
  • Sanofi
  • Boehringer Ingelheim International GmbH
  • Merck &Co., Inc
  • Grifols, SA
  • Almirall, SA
  • Genentech, Inc

第10章 アナリストの推奨事項

第11章 参考文献と調査手法

• 参考文献
• 調査手法

Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market is estimated to be valued at USD 20.35 Bn in 2025 and is expected to reach USD 30.41 Bn by 2032, growing at a compound annual growth rate (CAGR) of 5.9% from 2025 to 2032.

Figure. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Region 2025

Chronic obstructive pulmonary disease (COPD) refers to a group of lung diseases that cause airflow blockage and breathing-related problems. It includes emphysema and chronic bronchitis. Key causes of COPD include tobacco smoking, exposure to lung irritants in the workplace like dusts and fumes, and air pollution. The main symptoms of COPD include shortness of breath, cough, mucus (sputum) production, and wheezing. As COPD progresses, lung function deteriorates over time, resulting in breathlessness.

Market Dynamics:

Global chronic obstructive pulmonary disease (COPD) treatment market growth is driven by factors such as high prevalence of tobacco smoking, increasing air pollution levels worldwide, rising geriatric population, and a growing awareness about the disease and available therapeutic options. However, lack of complete cure for COPD and related complications like lung cancer can hamper the market growth. Pharmaceutical companies investing in research and development of novel biologic drugs for COPD can offer lucrative opportunities for the market growth. Companies are developing epinephrine auto-injectors, bronchodilators, inhaled corticosteroids and combination therapies to effectively treat COPD symptoms and exacerbations.

Key Features of the Study:

• This report provides an in-depth analysis of the global chronic obstructive pulmonary disease (COPD) treatment market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global chronic obstructive pulmonary disease (COPD) treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this include AstraZeneca, Orion Corporation, Mylan N.V., Teva Pharmaceutical Industries Ltd., GSK plc, Novartis AG, Sunovion Pharmaceuticals, Inc., CHIESI Farmaceutici SpA, Alembic Pharmaceuticals Ltd, Verona Pharmaceuticals, Theravance Biopharma, F. Hoffmann-La Roche Ltd, Sanofi, Boehringer Ingelheim International GmbH, Merck & Co., Inc, Grifols, S.A., Almirall, S.A, Genentech, Inc
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global chronic obstructive pulmonary disease (COPD) treatment market caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global chronic obstructive pulmonary disease (COPD) treatment market

Detailed Segmentation-

• By Drug Class:
  • Bronchodilators
  • Beta 2-Agonists
  • Anticholinergics
  • Theophyllines
  • Phosphodiesterase Type 4 Inhibitors
  • Corticosteroids
  • Others
• By Route of Administration:
  • Oral
  • Inhalation
• By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • AstraZeneca
  • Orion Corporation
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.
  • GSK plc
  • Novartis AG
  • Sunovion Pharmaceuticals, Inc.
  • CHIESI Farmaceutici SpA
  • Alembic Pharmaceuticals Ltd
  • Verona Pharmaceuticals
  • Theravance Biopharma
  • Hoffmann-La Roche Ltd
  • Sanofi
  • Boehringer Ingelheim International GmbH
  • Merck & Co., Inc
  • Grifols, S.A.
  • Almirall, S.A
  • Genentech, Inc

Table of Contents (TOC)

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Drug Class
  • Market Snapshot, By Route of Administration
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
• Impact Analysis
• Epidemiology
• Market Trends
• Key Developments
• Regulatory Scenario
• Manufacturer Revenue
• Acquisitions and Partnerships Scenario
• Product Launches/Approvals
• Funding and Investments
• PEST Analysis
• Porter's Analysis

4. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market - Impact of Coronavirus (COVID-19) Pandemic

• Overall Impact
• Government Initiatives
• COVID-19 Impact on the Market

5. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Drug Class, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Bronchodilators
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Beta 2-Agonists
  • Anticholinergics
  • Theophyllines
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Phosphodiesterase Type 4 Inhibitors
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Corticosteroids
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Route of Administration, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Oral
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Inhalation
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Distribution Channel, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hospital Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Retail Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Online Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Region, 2020 - 2032, (USD Bn)

• Introduction
  • Market Share Analysis, By Region, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Region, 2021-2032
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (USD Bn)
    • North Africa
    • Central Africa
    • South Africa

9. Competitive Landscape

• Company Profiles
  • AstraZeneca*
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Orion Corporation
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Mylan N.V.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Teva Pharmaceutical Industries Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • GSK plc
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Novartis AG
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Sunovion Pharmaceuticals, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • CHIESI Farmaceutici SpA
  • Alembic Pharmaceuticals Ltd
  • Verona Pharmaceuticals
  • Theravance Biopharma
  • F. Hoffmann-La Roche Ltd
  • Sanofi
  • Boehringer Ingelheim International GmbH
  • Merck & Co., Inc
  • Grifols, S.A.
  • Almirall, S.A
  • Genentech, Inc

10. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

11. References and Research Methodology

• References
• Research Methodology
• About us and Sales Contact